Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
The effect that inactivation of the RNA interference machinery has on endogenous levels of microRNAs and their gene targets
EF 2011-12
Résumé
The discovery of RNA interference has revolutionized the potential for gene therapy and personalized medicine. In this process a small portion of virtually any gene (a small RNA) in the human genome can use the body's own natural mechanism for eliminating that very same gene from being expressed and functionally active. Since any gene can be targeted, a tailored approach can be used to eliminate any gene that is mutated and responsible for a particular disease that an individual may have. The greatest challenge at present is effective delivery of this small RNA. While this barrier is being overcome, we are focused on another critical area: the safety of delivering this therapeutic. We know that by adding too much of these small RNAs, the natural use of the RNA interference system can be overwhelmed in the body leading to unintended and drastic consequences. We have addressed this by cataloging all of the small RNAs and target RNAs that are affected when one of the key genes in this pathway, argonaute-2, is eliminated in the mouse. These mice have severe defects in embryo growth. We have been able to characterize which small RNAs are required for this portion of embryo development and shown that they require argonaute-2 for identifying and removing their target genes. Our next goal is to characterize the small RNAs in adult mice with a given gene therapy target. We believe that the same small RNAs in our preliminary studies with argonaute-2 will be impaired when many non-specific small RNAs are delivered. With this information, we will be able to devise mechanisms to ensure that these small RNAs are monitored and acted upon to prevent adverse events in response to this form of gene therapy. The exciting potential of this gene therapy mechanism can then be realized and be applicable as a therapeutic to cure a broad range of genetic diseases.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
247335
Name
Valdmanis Paul N
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
The effect that inactivation of the RNA interference machinery has on endogenous levels of microRNAs and their gene targets
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Adeno Associated Virus; Allele Specific Expression; Argonautes; Embryo Development; Gene Therapy; High Throughput Sequencing; Liver Toxicity; Micrornas; Non-Coding Rnas; Rna Interference
Abstract
The discovery of RNA interference has revolutionized the potential for gene therapy and personalized medicine. In this process a small portion of virtually any gene (a small RNA) in the human genome can use the body's own natural mechanism for eliminating that very same gene from being expressed and functionally active. Since any gene can be targeted, a tailored approach can be used to eliminate any gene that is mutated and responsible for a particular disease that an individual may have. The greatest challenge at present is effective delivery of this small RNA. While this barrier is being overcome, we are focused on another critical area: the safety of delivering this therapeutic. We know that by adding too much of these small RNAs, the natural use of the RNA interference system can be overwhelmed in the body leading to unintended and drastic consequences. We have addressed this by cataloging all of the small RNAs and target RNAs that are affected when one of the key genes in this pathway, argonaute-2, is eliminated in the mouse. These mice have severe defects in embryo growth. We have been able to characterize which small RNAs are required for this portion of embryo development and shown that they require argonaute-2 for identifying and removing their target genes. Our next goal is to characterize the small RNAs in adult mice with a given gene therapy target. We believe that the same small RNAs in our preliminary studies with argonaute-2 will be impaired when many non-specific small RNAs are delivered. With this information, we will be able to devise mechanisms to ensure that these small RNAs are monitored and acted upon to prevent adverse events in response to this form of gene therapy. The exciting potential of this gene therapy mechanism can then be realized and be applicable as a therapeutic to cure a broad range of genetic diseases.
Competitiondate
201111
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Valdmanis, Paul N
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~